With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …
With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …
In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
Already a subscriber? Log in